NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH SIGNIFICANT IMPAIRMENT OF WORK PRODUCTIVITY: DATA FROM THE GLOBAL NASH REGISTRY™
Recommended Citation
Younossi ZM, Yilmaz Y, Yu ML, Wong VWS, Fernandez MIC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Buti M, Chan WK, Alswat KA, Hamid SS, Singal AK, Romero-Gómez M, Gordon SC, Roberts S, El Kassas M, Esmat G, Kugelmas M, Ong J, Lam BP, Younossi I, Racila A, Henry L, Stepanova M, and Alqahtani S. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH SIGNIFICANT IMPAIRMENT OF WORK PRODUCTIVITY: DATA FROM THE GLOBAL NASH REGISTRY™. Hepatol 2023; 77(5):E134-E135.
Document Type
Conference Proceeding
Publication Date
2-20-2023
Publication Title
Hepatology
Abstract
Background: Chronic liver diseases (CLDs) such as NAFLD can cause impairment of health-related quality of life and other patient-reported outcomes. Additionally, CLDs can be responsible for a reduction in work productivity due to both missed time at work (absenteeism) and decreased productivity while working (presenteeism). The aim was to evaluate work productivity impairment (WPI) in patients with NAFLD.
Methods: The Global NASH Registry™ includes NAFLD enrolled from real-life practices. The WPI scores including absenteeism and presenteeism (all range 0-1 with higher scores indicating greater work productivity impairment) were calculated from the Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) instrument.
Results: A total of 3421 NAFLD patients were included [18 countries; age 52±13 years, 47% male, 18% cirrhosis, 47% type 2 diabetes, 38% history of anxiety, 21% depression, 47% clinically overt fatigue, 48% employed]. For the subjects, WPI score [mean (SD)] was 0.205 (0.300) including 0.051 (0.182) absenteeism, 0.159 (0.250) presenteeism. In multivariate analysis, independent predictors of higher WPI (worse work productivity) among NAFLD subjects, adjusted for the country of enrollment, were history of anxiety (beta±SE = 0.069±0.020), depression (0.054±0.026), and clinically overt fatigue (0.095±0.019) (all p<0.05). On the other hand, there was no associations of WPI in NAFLD with obesity, type 2 diabetes, the presence of cirrhosis or FIB-4 score (all p>0.10). In comparison to historic data from clinical trial enrollees with biopsy-proven NASH (pooled N=2634, 67% diabetes, 33% cirrhosis, 51% employed), subjects with NAFLD enrolled from real-life practices had higher WPI: 0.205 (0.300) vs. 0.135 (0.230), absenteeism 0.051 (0.182) vs. 0.034 (0.140), presenteeism 0.159 (0.250) vs. 0.102 (0.175) (all p<0.01). However, after adjustment for clinico-demographic factors (age, sex, country of enrollment, comorbidities), the association of WPI of NAFLD patients with enrollment setting (real-life setting vs. clinical trial setting) was not significant (p=0.98).
Conclusion: Patients with NAFLD and NASH have significant impairment of their work productivity which could add substantially to the societal and personal burden of the disease.
Volume
77
Issue
5
First Page
E134
Last Page
E135
